Company / R&D Expense
BIODESIX INC R&D Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$12.0M
FY2025
5-year range
$9.6M / $13.1M
FY2021-FY2025
Trend
+25.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense returned to growth in FY2025 after 2 years of decline, reaching $12M.
Based on SEC 10-K filings.
$12M in FY2025 with a 5-year CAGR of +2.1%.
Improved from $10M to $12M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -2.9%
- 5-Year CAGR
- +2.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +2.1%, indicating consistent growth.
- In FY2025, r&d expense increased 25.5% year-over-year.
- Peak r&d expense was recorded in FY2022.
- Lowest r&d expense in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -4.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $12.0M | +25.5% |
| FY2024 | $9.6M | -4.3% |
| FY2023 | $10.0M | -23.8% |
| FY2022 | $13.1M | +2.4% |
| FY2021 | $12.8M | +18.2% |
| FY2020 | $10.8M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026